ExpreS2ion Biotechnologies: Valuation, Funding & Investors
ExpreS2ion Biotechnologies is a biotechnology company specializing in the development of innovative vaccines and immunotherapies. Utilizing its clinically validated ExpreS2 platform, the company focuses on advancing a pipeline that includes a lead breast cancer vaccine currently in Phase I trials. Based in Hørsholm, Denmark, ExpreS2ion aims to deliver cutting-edge solutions to address unmet medical needs in the field of immunotherapy.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $12M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $12M
- Latest Funding Round
- Investment
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Investment | $11.80M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Nils Berg | Investment |
| UBB Consulting AB | Investment |
| John Moll | Investment |
| Elvil AB | Investment |
| Paginera Invest AB | Investment |
| Peter Nilsson | Investment |
Similar Companies
A snapshot of private companies similar to ExpreS2ion Biotechnologies, helping you discover and navigate related company profiles.









